ACADEMIA
JAMS’ Draft of Revised Guidelines Ups Ante for COI Disclosures in Clinical Trials
The Japanese Association of Medical Sciences’ (JAMS) revised guidelines on conflicts of interest (COI) are expected to bolster the disclosure of COI for clinical trials, in particular, amid a scandal surrounding Novartis Pharma’s blood pressure drug Diovan (valsartan). The JAMS’…
To read the full story
Related Article
- JAMS COI Panel to Nudge JPMA to Create Funding Database
November 19, 2013
ACADEMIA
- Japan Atherosclerosis Society Proposes 3-Tier Lp(a) Risk Framework
September 16, 2026
- Clinical Value of Lp(a) Unchanged despite Pelacarsen PIII Miss: KOL
September 16, 2026
- Yanagisawa Wins Lasker Award for Unlocking Orexin’s Role in Sleep
September 10, 2026
- Generic Shortage Response Evolves into Wakayama’s 1st Regional Formulary
September 3, 2026
- Japan Cancer Database Initiative Aims to Bolster Trial Environment
August 26, 2026
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…





